- « Previous
- Clinical Pharmacology
- Next »
Actiq
Clinical Pharmacology
Actiq
The absorption pharmacokinetics of fentanyl from the oral transmucosal dosage form is a combination of an initial rapid absorption from the buccal mucosa and a more prolonged absorption of swallowed fentanyl from the GI tract. Both the blood fentanyl profile and the bioavailability of fentanyl will vary depending on the fraction of the dose that is absorbed through the oral mucosa and the fraction swallowed.
Absolute bioavailability, as determined by area under the concentration- time curve, of 15 mcg/kg in 12 adult males was 50% compared to intravenous fentanyl.
Normally, approximately 25% of the total dose of Actiq is rapidly absorbed from the buccal mucosa and becomes systemically available. The remaining 75% of the total dose is swallowed with the saliva and then is slowly absorbed from the GI tract. About 1/3 of this amount (25% of the total dose) escapes hepatic and intestinal first-pass elimination and becomes systemically available. Thus, the generally observed 50% bioavailability of Actiq is divided equally between rapid transmucosal and slower GI absorption. Therefore, a unit dose of Actiq , if chewed and swallowed, might result in lower peak concentrations and lower bioavailability than when consumed as directed.
Dose proportionality among four of the available strengths of Actiq (200, 400, 800, and 1600 mcg) has been demonstrated in a balanced crossover design in adult subjects (n=11). Mean serum fentanyl levels following these four doses of Actiq are shown in Figure 1. The curves for each dose level are similar in shape with increasing dose levels producing increasing serum fentanyl levels. Cmax and AUC0→∞ increased in a dose-dependent manner that is approximately proportional to the Actiq administered.
Figure 1. Mean Serum Fentanyl Concentration (ng/mL) in Adult
Subjects Comparing 4 Doses of Actiq
![]() |
The pharmacokinetic parameters of the four strengths of Actiq tested in the dose-proportionality study are shown in Table 3. The mean Cmax ranged from 0.39 - 2.51 ng/mL. The median time of maximum plasma concentration (Tmax) across these four doses of Actiq varied from 20 - 40 minutes (range of 20 - 480 minutes) as measured after the start of administration.
Table 3: Pharmacokinetic Parameters* in Adult Subjects Receiving
200, 400, 800, and 1600 mcg Units of Actiq
| Pharmacokinetic Parameter |
200 mcg | 400 mcg | 800mcg | 1600 mcg |
| Tmax, minute median (range) |
40 (20-120) |
25 (20-240) |
25 (20-120) |
20 (20-480) |
| Cmax, ng/mL mean (%CV) |
0.39 (23) | 0.75 (33) | 1.55 (30) | 2.51 (23) |
| AUC0-1440, ng/mL minute mean (%CV) |
102 (65) | 243 (67) | 573 (64) | 1026 (67) |
| t1/2, minute mean (%CV) |
193 (48) | 386 (115) | 381 (55) | 358 (45) |
| * Based on arterial blood samples. | ||||
Distribution
Fentanyl is highly lipophilic. Animal data showed that following absorption, fentanyl is rapidly distributed to the brain, heart, lungs, kidneys and spleen followed by a slower redistribution to muscles and fat. The plasma protein binding of fentanyl is 80-85%. The main binding protein is alpha-1- acid glycoprotein, but both albumin and lipoproteins contribute to some extent. The free fraction of fentanyl increases with acidosis. The mean volume of distribution at steady state (Vss) was 4 L/kg.
Metabolism
Fentanyl is metabolized in the liver and in the intestinal mucosa to norfentanyl by cytochrome P450 3A4 isoform. Norfentanyl was not found to be pharmacologically active in animal studies [see DRUG INTERACTIONS].
Elimination
Generic Name: Fentanyl Citrate
- « Previous
- Clinical Pharmacology
- Next »
Cancer and Exercise
Resting to conserve energy may not be the best remedy for fatigue during radiation therapy. See more WebMD Videos »
Cancer
Get the latest treatment options.

